These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20579113)

  • 1. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
    Oldenburg J; Goudemand J; Valentino L; Richards M; Luu H; Kriukov A; Gajek H; Spotts G; Ewenstein B
    Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD; Collins PW; Hay CR; Shapiro AD; Gruppo RA; Berntorp E; Bray GL; Tonetta SA; Schroth PC; Retzios AD; Rogy SS; Sensel MG; Ewenstein BM;
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
    Iorio A; Marcucci M; Cheng J; Oldenburg J; Schoenig-Diesing C; Matovinovic E; Romanov V; Thabane L
    Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
    Pollmann H; Klamroth R; Vidovic N; Kriukov AY; Epstein J; Abraham I; Spotts G; Oldenburg J
    Ann Hematol; 2013 May; 92(5):689-98. PubMed ID: 23324986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS; Shapiro AD; Liesner RJ; Hernández Navarro F; Warrier I; Schroth PC; Spotts G; Ewenstein BM;
    J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
    J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
    Dhillon S
    Drugs; 2012 May; 72(7):987-1007. PubMed ID: 22564135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A.
    Motwani J; Guillet B; Blatny J; Schilling FH; Wibaut B; Goldstine J; Nagy A; Doralt J; Engl W; Tangada S; Spotts G
    Haemophilia; 2020 May; 26(3):478-486. PubMed ID: 32338433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor development, safety, and efficacy of Advate
    Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
    Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.
    Romanov V; Marcucci M; Cheng J; Thabane L; Iorio A
    Thromb Haemost; 2015 Jul; 114(1):56-64. PubMed ID: 26017627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor development, safety and efficacy of Advate
    Fukutake K; Taki M; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
    Int J Hematol; 2019 Mar; 109(3):336-345. PubMed ID: 30604312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
    Auerswald G; Thompson AA; Recht M; Brown D; Liesner R; Guzmán-Becerra N; Dyck-Jones J; Ewenstein B; Abbuehl B
    Thromb Haemost; 2012 Jun; 107(6):1072-82. PubMed ID: 22476554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.
    Zhang L; Zhao Y; Sun J; Wang X; Yu M; Yang R
    Haemophilia; 2011 Mar; 17(2):191-5. PubMed ID: 20860578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.